BUPRENORPHINE MARKET ANALYSIS

The global buprenorphine market is estimated to be valued at US$ 5.52 Billion in 2023 and is expected to exhibit a CAGR of 14.9% during the forecast period (2023-2030).

Analysts’ Views on Global Buprenorphine Market:

It has been reported that buprenorphine is used for the treatment of opioid use disorders such as opioid addiction. According to the Centre for Addiction and Mental Health, buprenorphine is a long-acting opioid drug used to treat opioid addiction in substitution of shorter-acting opioids including heroin, oxycodone, fentanyl, and hydromorphone. Long-acting drugs have a shorter duration of action and last longer in the body. Buprenorphine's effects last for 24 to 36 hours. Moreover, the increasing number of people suffering from opioid use disorder is expected to drive the growth of the global buprenorphine market over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information on April 29, 2023, in the U.S. and throughout the world, opioid use disorder and addiction are still at pandemic levels. 16 million people globally and 3 million US citizens have experienced or are presently experiencing opioid use disorder (OUD). More than 500,000 people in the U.S. are dependent on heroin.

Figure 1. Global Buprenorphine Market Share (%), by Application, 2023

To learn more about this report, request a free sample copy

Global Buprenorphine Market – Driver

Approval of Buprenorphine Treatment for Opioid Use Disorder, by Regulatory Authorities

Increasing approval of buprenorphine treatment for opioid use disorder by regulatory authorities is expected to drive the growth of the global buprenorphine market over the forecast period. For instance, on May 23, 2023, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use to treat moderate to severe opioid use disorder. Brixadi is available in two formulations: a weekly injection that can be used in patients who have started treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, and a monthly version for patients already being treated with buprenorphine.

Increasing prevalence of cancer around the world, is expected to drive segment growth over the forecast period as buprenorphine is prescribed for the control of cancer pain. For instance, according to the data published in March 2022, by World Cancer Research Fund International, There were an estimated 18.1 million cancer cases around the world in 2020. 9.3 million of these instances involved men, while 8.8 million involved women.

Figure 2. Global Buprenorphine Market Share (%), by Region, 2023

To learn more about this report, request a free sample copy

Global Buprenorphine Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global buprenorphine market over the forecast period. North America holds 45.1% of the market share due to the increasing prescriptions of buprenorphine in the region. For instance, according to an article published by the American Medical Association in January 2020, buprenorphine is seen as having the best chance of increasing access among the drugs that the US Food and Drug Administration has licensed for treating opioid use disorder. In the US, estimates of office visits containing prescriptions for buprenorphine increased from 1.9 million to 4.3 million between 2009 and 2018.

Global Buprenorphine Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 pandemic is expected to hamper the growth of the global buprenorphine market owing to restrictions in the supply chain of drugs during the COVID-19 pandemic. For instance, according to data reported by the United Nations Office on Drugs and Crime in July 2020, the effective measures taken to control the spread of the COVID-19 pandemic have, in the end, badly affected to drug supply chain. Many countries across the world have reported an overall shortage of many types of drugs at the retail level. The supply chain affected the transport and production of all kinds of drugs, which is expected to hamper the global buprenorphine market.

The coronavirus (COVID-19) pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses in the healthcare sector. Players operating in the global buprenorphine market were facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include the supply of raw materials required for manufacturing instruments and accessories used in cell expansion applications, along with irregularities in transportation facilities.

Global Buprenorphine Market Segmentation:

The global buprenorphine market report is segmented into application, route of administration, distribution channel, and region

• Based on application, the market is segmented into analgesic and opioid antagonist. Out of which, the opioid antagonist segment is expected to hold a dominant position in the buprenorphine market during the forecast period, and this is attributed to the increasing number of opioid use disorders among the population.
• Based on route of administration, the market is segmented into injectables, sublingual, and transdermal. Out of which, the sublingual segment is expected to hold a dominant position in the buprenorphine market during the forecast period, and this is because sublingual formula has extensive use in the treatment of opioid addiction.
• Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the retail pharmacies segment is expected to dominate the market over the forecast period, and this is attributed to the increase in the number of new retail pharmacies.

Among all segmentation, the distribution channel segment has the highest potential due to the increasing number of new pharmacies in countries such as the U.S. over the forecast period. For instance, according to the data published in August 2021 by the Commonwealth Fund, a private U.S. foundation that promotes a high-performing health care system, over the past three decades, the pharmaceutical business has grown in the U.S. In the U.S., there are over 60,000 retail pharmacies; 2/3 of them are retail chains, supermarkets, or mass merchants, and 1/3 are independent pharmacies.

Global Buprenorphine Market Cross Sectional Analysis:

In the application segment, the analgesic segment is dominating in the North America region due to the increasing number of people who experience pain. Analgesics are drugs that treat pain. For instance, according to data published on April 14, 2023,  by the Centers for Disease Control and Prevention, between 2019 and 2021, the prevalence of pain among U.S. adults ranged from 20.5% to 21.8% of the population. In 2021, an estimated 51.6 million U.S. adults experienced chronic pain.

Global Buprenorphine Market: Key Developments

• In August 2020, the U.S. Food and Drug Administration approved Olinvyk of Trevena, Inc., an opioid agonist, for the management of moderate to severe acute pain in adults where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.

Global Buprenorphine Market: Key Trends

Regulatory authorities are issuing licenses for the new drug manufacture and is expected to drive the market growth over the forecast period

In a nation like India, the Gujarat Food and Drug Control Administration (FDCA) has  issued licenses for new medication manufacturers, which is anticipated to fuel market expansion over the forecast period. For instance, between April 1, 2020, and March 31, 2023, the Gujarat Food and Drug Control Administration (FDCA) issued a total of 2,267 licenses for the new manufacture of different types of drugs, such as allopathic medicine, cosmetics, etc.

Global Buprenorphine Market: Restraint

• Adverse Side Effects Buprenorphine: The global buprenorphine market can be hindered by the increasing side effects of buprenorphine over the forecast period. For instance, according to an article published by the National Center for Biotechnology Information, buprenorphine exerts some anticholinergic-like effects and may cause central nervous system depression, hypotension, QT prolongation, and a lower seizure threshold. Buprenorphine also has a number of other adverse effects, such as urine retention, sweating, dry mouth, miosis, headache, nausea, vomiting, sleepiness, dizziness, and memory loss. Since buprenorphine is one of the most valuable drugs on the market, to counter balance this restrain additional research and development efforts are needed to reduce its side effects.

Global Buprenorphine Market - Key Players

Major players operating in the global buprenorphine market include Mallinckrodt, Noramco, Unichem Laboratories Ltd., Sanofi, Johnson Matthey, Arevipharma Gmbh, Resonance Laboratories Pvt. Ltd., Sun Pharmaceutical Industries Limited, Rusan Pharma Ltd. Micro Orgo Chem, Faran Shimi Pharmaceutical, Indivior PLC, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC.

Defination: Buprenorphine, a synthetic opioid, treats pain and opioid addiction. It is a synthetic analog of thebaine, an alkaloid compound derived from the poppy flower. It is a Schedule III drug, which means that it has some potential for moderate or low physical dependence or high psychological dependence.